
Aytu BioScience (AYTU) Stock Forecast & Price Target
Aytu BioScience (AYTU) Analyst Ratings
Bulls say
Aytu BioPharma is supported by a stronger-than-expected fiscal Q4 FY26 performance, with revenue of $16.1 million rising 6% year over year and pro forma EPS of $0.03, both ahead of estimates. Its bullish case is anchored by EXXUA, which launched in Q4 2025 and has been described as highly encouraging, while its differentiated profile avoids labeled warnings for sexual dysfunction or weight gain and has shown symptom improvement in trials of more than 5,000 patients. With EXXUA targeting the $22 billion U.S. prescription MDD market, the company has substantial upside if commercialization scales, and even conservative FY27/FY28 expectations point to meaningful revenue growth and a path to profitability.
Bears say
Aytu BioPharma is exposed to a wide range of fundamental risks that could impair execution, including balance sheet and liquidity pressure, commercialization setbacks, and adverse shifts in investor sentiment toward biotech stocks. Its prospects also depend on successfully proving safety and efficacy in clinical trials and after FDA/postmarket approval, while maintaining regulatory approvals, securing reimbursement, and sustaining physician and patient adoption in a competitive market. Given its reliance on a single operating segment and a revenue mix concentrated in the ADHD Portfolio, any weakness in product performance, macroeconomic conditions, or healthcare priority shifts could disproportionately hurt results.
This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.
Aytu BioScience (AYTU) Analyst Forecast & Price Prediction
Start investing in Aytu BioScience (AYTU)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aytu BioScience (AYTU) Forecast
Aytu BioScience (AYTU) Analyst Forecast & Price Prediction
Start investing in Aytu BioScience (AYTU)
Order type
Buy in
Order amount
Est. shares
0 shares